治療性血漿置換市場－全球產業規模、佔有率、趨勢、機會和預測（按產品、技術、適應症、最終用戶、地區和競爭細分，2020 年至 2030 年）

2024 年全球治療性血漿置換市場價值為 16.4 億美元，預計到 2030 年將達到 25.7 億美元，預測期內的複合年成長率為 7.77%。治療性血漿置換 (TPE)，也稱為血漿置換，是一種血管內血液技術，用於從客戶血液中分離致病物質，並用替代液（例如白蛋白溶液或新鮮冷凍血漿）替換它們。這些物質包括感染性自體抗體、免疫複合物、冷球蛋白和含膽固醇的脂蛋白。 TPE 用於治療各種自體免疫疾病、腎臟疾病、血液疾病等，有助於市場擴張。此外，治療性血漿置換 (TPE) 具有降低血漿黏度的顯著益處。它廣泛應用於慢性病的管理中，作為一線或二線療法，或作為支持療法。在血漿置換過程中，從其他血液成分中提取出含有毒素和其他異常物質的大量血漿，並用替代液（例如新鮮冷凍血漿 (FFP) 或白蛋白）取代。

關鍵市場促進因素

神經系統、腎臟和血液系統疾病盛行率高

主要市場挑戰

血漿置換術相關風險

主要市場趨勢

持續進步

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球治療性血漿置換市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品（消耗品、設備）
  • 依技術（離心、膜分離）
  • 依適應症（神經系統疾病、血液系統疾病、腎臟疾病、代謝性疾病、其他）
  • 按最終使用者（血液採集中心和血液成分提供者、醫院和診所、輸血中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美治療性血漿置換市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲治療性血漿置換市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太地區治療性血漿置換市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲治療性血漿置換市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲治療性血漿置換市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 併購
• 產品發布

第 13 章：全球治療性血漿置換市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica SpA
• Kawasumi Laboratories
• Terumo Corporation

第 16 章：策略建議

第17章調查會社について,免責事項

Global Therapeutic Plasma Exchange Market was valued at USD 1.64 Billion in 2024 and is expected to reach USD 2.57 Billion by 2030 with a CAGR of 7.77% during the forecast period. Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an endovascular blood technique utilized to separate pathogenic substances from clients' blood and replace them with replacement fluid, such as albumin solution or fresh frozen plasma. These substances encompass infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing to market expansion. Additionally, therapeutic plasma exchange (TPE) offers the significant benefit of reducing plasma viscosity. It is widely performed in the management of chronic diseases as a first-line or second-line therapy, or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers

High prevalence of Neurological, Renal, And Hematological Disorders

The high prevalence of chronic diseases, such as nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. Additionally, there has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market. The most common indications for TPE therapy are nephrology-related disorders, as well as its use in the treatment of myasthenia gravis, Guillain Barre syndrome (GBS), and chronic inflammatory demyelinating polyneuropathy. Currently, the trend in therapeutic plasma exchange involves the use of highly permeable filters and standard dialysis equipment, often referred to as membrane plasma separation (MPS). In the US, the "Plasmaflo" membrane from Asahi Medical (Asahi Kasei Kuraray Medical Co., Ltd, Japan) is widely used.

Key Market Challenges

Risk Associated with Plasmapheresis Procedures

During the plasmapheresis procedure, a portion of blood is extracted from the human body, and specific replacement fluids like albumin, fresh frozen plasma (FFP), electrolyte solutions, purified protein products, and starches are administered intravenously to maintain intravascular osmotic pressure. Although generally considered safe, there are still several associated risks. Risk factors include infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. One of the most frequent side effects of plasmapheresis is hypotension, characterized by symptoms such as faintness, blurred vision, dizziness, sweating, or abdominal cramps. However, prompt treatment can effectively manage these symptoms. Some patients may experience numbness or tingling around the mouth or nose due to the effect of the anticoagulant citrate on calcium levels in the body. In rare cases, bleeding may occur during the procedure as a result of anticoagulants added to the blood, potentially leading to irregular heartbeat and cardiac arrest if not promptly addressed. Allergic reactions, itching, and rash may also occur as a response to the replacement fluids, but these can be easily treated with intravenous medication. These side effects may impede the widespread adoption of plasmapheresis, thereby limiting market growth to some extent.

Key Market Trends

Continuous Advancement

Continuous technological advancements have significantly enhanced and refined high-precision methods. These advancements not only improve patient satisfaction but also enhance the processing of goods derived from blood and plasma. In comparison to other techniques such as membrane separation methods, this method requires minimal blood flow, making it a more advanced approach for facilitating blood collection through the patient's antecubital or radial veins. Moreover, these technological advancements allow for more precise control of hydration status, resulting in greater hemodynamic stability during treatment. Additionally, patients benefit from improved comfort and safety during therapeutic plasma exchange (TPE) procedures. These remarkable technological developments create lucrative opportunities within the market.

Key Market Players

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic Plasma Exchange Market, By Product:

• Consumables
• Devices

Therapeutic Plasma Exchange Market, By Technology:

• Centrifugation
• Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

• Neurological Disorders
• Haematology Disorders
• Renal Disorders
• Metabolic Disorders
• Others

Therapeutic Plasma Exchange Market, By End User:

• Blood Collection Centres & Blood Component Providers
• Hospitals & Clinics
• Blood Transfusion Centres
• Others

Therapeutic Plasma Exchange Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Devices)
  • 5.2.2. By Technology (Centrifugation, Membrane Separation)
  • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
  • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Asahi Kasei Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Baxter International Inc
• 15.3. B. Braun Melsungen AG
• 15.4. Cerus Corporation
• 15.5. Fresenius Kabi AG
• 15.6. Haemonetics Corporation
• 15.7. Hemacare Corporation
• 15.8. IncMedica S.p.A.
• 15.9. Kawasumi Laboratories
• 15.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer